200 related articles for article (PubMed ID: 10222349)
1. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
2. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
4. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
5. Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.
Copur MS; Wurdeman JM; Nelson D; Ramaekers R; Gauchan D; Crockett D
Oncol Res; 2018 Apr; 26(3):515-518. PubMed ID: 29229020
[TBL] [Abstract][Full Text] [Related]
6. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Rack B; Jückstock J; Trapp E; Weissenbacher T; Alunni-Fabbroni M; Schramm A; Widschwendter P; Lato K; Zwingers T; Lorenz R; Tesch H; Schneeweiss A; Fasching P; Mahner S; Beckmann MW; Lichtenegger W; Janni W;
Tumour Biol; 2016 Oct; 37(10):13769-13775. PubMed ID: 27481512
[TBL] [Abstract][Full Text] [Related]
7. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
11. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
12. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
15. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
[TBL] [Abstract][Full Text] [Related]
16. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
17. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
[TBL] [Abstract][Full Text] [Related]
19. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the BT-1 serum assay for breast cancer.
Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
